Titan International reported Q1 2026 revenue growth to $505.1M but also wider losses of $24.2M and weaker cash flow, highlighting operational difficulties. Management projects full-year 2026 revenue between $1.85B and $1.95B with EBITDA of $105M to $115M, but ongoing challenges in agriculture and construction markets, plus dependence on government support, cloud the outlook. The upcoming Q2 2026 results on July 29 are critical for assessing backlog and guidance before any rating change. The stock remains a 'hold' due to these persistent sector headwinds despite its attractive valuation.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
Spain won the 2026 FIFA World Cup, a victory spotlighting Chiliz’s fan token ecosystem as both Spain and Argentina—finalists—are Chiliz partners. This marks the first World Cup final between two fan token nations, showcasing tokenized fan engagement'...
Margin debt in the U.S. increased for the third consecutive month in June, reaching a record $1.53 trillion. This represents a 7.9% rise from May and a 51.5% increase compared to June last year. Adjusted for inflation, the growth remains significant ...
